Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05043675|
Recruitment Status : Recruiting
First Posted : September 14, 2021
Last Update Posted : July 1, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease||Drug: [18F]APN-1607||Early Phase 1|
- To expand the safety and tolerability profile for the administration of [18F]APN-1607 and PET scanning.
- To assess regional patterns of [18F]APN-1607 uptake.
- To evaluate the relationship between regional measures of [18F]APN-1607 uptake and measurements of AD disease severity, such as National Institute on Aging and Alzheimer's Association (NIA-AA) diagnosis, Mini-mental Status Exam (MMSE) score, and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAScog).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Director of Nuclear Medicine Department|
|Actual Study Start Date :||September 10, 2021|
|Estimated Primary Completion Date :||September 10, 2024|
|Estimated Study Completion Date :||September 10, 2024|
For the injection, subjects will receive a target dose of 0.1~0.15mCi/Kg [18F]APN-1607 as a bolus injection.
Subjects will receive one injection of [18F]APN-1607 (0.1~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
Other Name: [18F]PBB3
- Assessment of [18F]APN-1607 Uptake Patterns by Regional SUV Values [ Time Frame: 36 months ][18F]APN-1607 uptake patterns will be assessed in regions of interest (ROIs) which relevant to AD pathology. Standard uptake value (SUV) will be calculated for each ROI, and standardized uptake value ratios (SUVRs) will be calculated by normalizing SUV of ROIs to the SUV of relevant reference region.
- Safety and Tolerability Profile Measured by Adverse Events (AEs) [ Time Frame: 36 months ]Safety and tolerability profile for the administration of [18F]APN-1607 and positron emission tomography (PET) scanning are measured by number of participants with adverse events (AEs).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||45 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female aged 45 to 80 years, inclusive.
- Has a diagnosis of AD dementia according to NIA-AA criteria, including significant impairment of activities of daily living.
- Has a CDR score ≥ 0.5 at screening.
- Has a MMSE score ≤ 25.
- Brain MRI supports the diagnosis of AD and there is no evidence of other nervous system diseases.
- Medications taken for symptomatic treatment of AD must have been stable for 30 days prior to screening and through completion of the neuropsychological battery.
- If necessary, the subject can be accompanied by nursing staff.
- Written informed consent must be obtained before any assessment is performed.
- Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year (ie, 12 consecutive months with no menses without an alternative medical cause) or, if they are of childbearing potential, must commit to use a barrier contraception method or to abstinence for the duration of the study and must have negative serum and urine pregnancy tests.
- Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method (ie, condom), or to abstinence for the study duration.
- Male subjects must not donate sperm for the study duration.
- Willing and able to participate in all study procedures.
- Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease.
- Implants, such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI.
- Intolerance to MRI noise or hermetic phobia.
- Prior participation in other research protocols or clinical care in the last year in addition to the radiation exposure expected from participation in this clinical study, such that radiation exposure exceeds local guidelines, eg, above an effective dose of 50 mSv.
- Current or prior history (within the last 10 years) of alcohol or drug abuse.
- Pregnant, lactating or breastfeeding.
- Unsuitable veins for repeated venipuncture
- Has received any investigational drug or device for any purpose within 30 days of screening (or 5 half-lives of the drug, whichever is longer).
- Known hypersensitivity to [18F]APN-1607 or its excipients
- Has received a non-vaccine investigational treatment for Aβ within the last 3 months.
- Has received a non-vaccine investigational treatment for tau within the last 3 months.
- Any situation that the presiding officer of this study believes may cause harm or potential harm to any link related to this test.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05043675
|Contact: Feng Wangfirstname.lastname@example.org|
|Contact: Wenyu Wuemail@example.com|
|Nanjing First Hospital||Recruiting|
|Contact: Feng Wang, Ph.D +8602552271491 firstname.lastname@example.org|
|Contact: Wenyu Wu, M.D +8602552271456 email@example.com|
|Principal Investigator: Feng Wang, Ph.D|
|Study Director:||Feng Wang||Nanjing First Hospital, Nanjing Medical University|
|Responsible Party:||FengWang, Director of nuclear medicine department, Nanjing First Hospital, Nanjing Medical University|
|Other Study ID Numbers:||
|First Posted:||September 14, 2021 Key Record Dates|
|Last Update Posted:||July 1, 2022|
|Last Verified:||June 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Central Nervous System Diseases
Nervous System Diseases